Product information

From Health Canada

No match found

No other product was found from this company.

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Approved

Current status date:

2022-12-06

Product name:

PREHEVBRIO

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02533286

Product Monograph/Veterinary Labelling:

Date: 2022-12-06 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

VBI VACCINES INC.
310 Hunt Club Road
Ottawa
Ontario
Canada K1V 1C1

Class:

Human

Dosage form(s):

Suspension

Route(s) of administration:

Intramuscular

Number of active ingredient(s):

1

Schedule(s):

Schedule D

 

American Hospital Formulary Service (AHFS): See footnote 3

80:12.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

J07BC01 HEPATITIS B, PURIFIED ANTIGEN

Active ingredient group (AIG) number:See footnote5

0119570001

List of active ingredient(s)
Active ingredient(s) Strength
HEPATITIS B SURFACE ANTIGEN (RECOMBINANT) 10 MCG / ML

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Pharmacovigilance/Monitoring Activity
Registry
Version 4.0.2
Date modified: